(UroToday.com) Dr. Karim Fizazi presents the results of the PEACE-1 randomized phase 3 clinical trial with a focus on the impact of adding abiraterone acetate + prednisone to ADT+docetaxel on radiographic progression-free survival (rPFS) during this session at the 2021 European Association of Urology, (EAU) annual meeting. The results of the PEACE-1 randomized phase 3 clinical trial were previously presented at ASCO 2021.